Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced NSCLC With EGFR Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT06095934
What this trial is testing

Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment

Who this might be right for
NSCLCEGFR Gene Mutation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 20
Large-scale testing (Phase 3)UnknownNCT03866499
What this trial is testing

BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

Who this might be right for
NSCLC
Beta Pharma Shanghai 369
Large-scale testing (Phase 3)Ended earlyNCT04427072
What this trial is testing

Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 22
Not applicableStudy completedNCT00899756
What this trial is testing

Epidermal Growth Factor Receptor Mutations in the Blood of Patients With Advanced Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 50
Testing effectiveness (Phase 2)UnknownNCT05821933
What this trial is testing

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

Who this might be right for
NSCLC
RemeGen Co., Ltd. 106
Large-scale testing (Phase 3)UnknownNCT03008109
What this trial is testing

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Who this might be right for
Advanced CancerLung Cancer, Nonsmall Cell
Zaiwen Fan 80
Large-scale testing (Phase 3)UnknownNCT05132413
What this trial is testing

SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Who this might be right for
Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 561
Testing effectiveness (Phase 2)Looking for participantsNCT06631989
What this trial is testing

Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc. 100
Large-scale testing (Phase 3)Looking for participantsNCT05445791
What this trial is testing

Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations

Who this might be right for
Non Small Cell Lung Cancer
Instituto Nacional de Cancerologia de Mexico 312
Large-scale testing (Phase 3)Study completedNCT01024413
What this trial is testing

Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations

Who this might be right for
Thoracic Neoplasms
Chinese Society of Lung Cancer 256
Not applicableStudy completedNCT03721289
What this trial is testing

Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 463
Testing effectiveness (Phase 2)Ended earlyNCT04402008
What this trial is testing

Study of Poziotinib in Japanese Patients With NSCLC

Who this might be right for
NSCLC
Spectrum Pharmaceuticals, Inc 42
Testing effectiveness (Phase 2)UnknownNCT05338619
What this trial is testing

Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Who this might be right for
Non-small Cell Lung Cancer Stage IIIEGFR Positive Non-small Cell Lung CancerNon-squamous Non-small-cell Lung Cancer
Sung Yong Lee 77
Testing effectiveness (Phase 2)UnknownNCT02725918
What this trial is testing

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Who this might be right for
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials 150
Early research (Phase 1)UnknownNCT06362980
What this trial is testing

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations

Who this might be right for
NSCLC
National Cancer Center, China 20
Early research (Phase 1)Study completedNCT03452150
What this trial is testing

D-0316 First Time in Patients Ascending Dose Study

Who this might be right for
Advanced Non Small Cell Lung Cancer
InventisBio Co., Ltd 84
Early research (Phase 1)Looking for participantsNCT05681780
What this trial is testing

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Who this might be right for
Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 20
Not applicableLooking for participantsNCT06102928
What this trial is testing

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Who this might be right for
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Kunming Medical University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03974022
What this trial is testing

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

Who this might be right for
Non-Small Cell Lung Cancer
Dizal Pharmaceuticals 315
Testing effectiveness (Phase 2)WithdrawnNCT02297425
What this trial is testing

Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Who this might be right for
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer
Next Page